HCA Healthcare
HCA
$378.85
+4.19%
HCA Healthcare is the largest owner and operator of acute-care hospitals in the United States, with 190 hospitals and over 2,500 outpatient facilities across 19 states and a small UK presence. As a dominant player in the healthcare services industry, it benefits from scale, geographic diversification, and a strong brand in hospital operations. The current investor narrative centers on HCA's ability to sustain growth amid an aging population and rising healthcare demand, while navigating regulatory headwinds, payer mix shifts, and recent stock volatility driven by broader market selloffs and sector-specific concerns.…
HCA
HCA Healthcare
$378.85
Related headlines
Investment Opinion: Should I buy HCA Today?
Rating: Buy. HCA Healthcare offers a compelling risk/reward at current levels, with strong operational momentum and a discounted valuation. The analyst consensus is bullish (5 Buy, 1 Neutral) with an average EPS estimate of $48.73, implying a forward PE of 12.29x. Supporting evidence: (1) Revenue grew 6.72% YoY to $19.5B in Q4 2025, with consistent sequential acceleration. (2) Net margin expanded to 9.62% from 7.86% a year ago, and operating margin reached 16.29%. (3) Free cash flow of $7.7B TTM yields ~7.1%, well above the sector average. (4) PEG ratio of 0.57 indicates undervaluation relative to earnings growth. Risks: (1) High leverage (debt-to-equity -8.33) could amplify earnings volatility. (2) Payer mix shifts toward government programs may pressure margins. (3) Technical weakness with 3-month decline of -17.94% suggests continued selling pressure. This Buy rating would downgrade to Hold if forward PE exceeds 15x or if revenue growth decelerates below 4%. Upgrade to Strong Buy if the stock breaks above $450 with improving relative strength. Valuation verdict: HCA is undervalued relative to its growth rate and industry peers, but fairly valued on a historical PE basis (16.31x trailing vs 5-year range of 8-20x).
Sign up to view all
HCA 12-Month Price Forecast
HCA Healthcare presents a compelling value opportunity with strong operational momentum. The 6.72% revenue growth, expanding margins, and robust free cash flow contrast sharply with the stock's 17.94% 3-month decline, creating a potential mispricing. The forward PE of 12.29x is a 26% discount to the industry, and the PEG of 0.57 suggests the market is not pricing in the growth trajectory. However, high leverage and technical weakness warrant caution. The stance would upgrade to high confidence if the stock breaks above $450 with improving relative strength, and downgrade to neutral if revenue growth falls below 5% or margins contract.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on HCA Healthcare's 12-month outlook, with a consensus price target around $492.51 and implied upside of +30.0% versus the current price.
Average Target
$492.51
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$303 - $493
Analyst target range
HCA is covered by 6 analysts, with a consensus leaning bullish. The average estimated EPS for the current fiscal year is $48.73, with a low of $47.80 and a high of $49.79. The average revenue estimate is $97.956 billion, implying a 5.5% growth from the trailing twelve months. While specific price targets are not provided, the EPS estimates imply a forward PE of 12.29x at the current price, which is below the industry average. Recent ratings from firms like TD Cowen (Buy), Mizuho (Outperform), UBS (Buy), and Jefferies (Buy) indicate strong institutional support, while JP Morgan maintains a Neutral stance. The consensus is bullish, with 5 out of 6 analysts rating it Buy or equivalent, and only one Neutral. The absence of Sell ratings suggests limited downside risk from a sentiment perspective. The range of EPS estimates ($47.80 to $49.79) is relatively tight, indicating high conviction among analysts. The high estimate of $49.79 implies a forward PE of 12.0x, assuming growth acceleration and margin expansion. The low estimate of $47.80 still represents a 17.5% earnings yield, providing a margin of safety. The wide range of revenue estimates ($96.5B to $99.6B) reflects uncertainty around patient volumes and payer mix, but overall, analyst sentiment is positive.
Bulls vs Bears: HCA Investment Factors
HCA Healthcare presents a classic value-versus-momentum tension. On the bull side, the company delivers strong revenue growth (6.72% YoY), expanding margins (net margin up to 9.62%), and a compelling forward PE of 12.29x with a PEG of 0.57. Robust free cash flow of $7.7 billion supports the thesis. However, bears point to significant market underperformance (3-month -17.94% vs S&P +11.11%), high leverage (debt-to-equity -8.33), and regulatory risks from government payer exposure. The single most important tension is whether HCA's operational strength can overcome its technical weakness and leverage concerns. Currently, the bull case has stronger fundamental evidence, but the bear case dominates price action. Resolution will depend on upcoming earnings and margin trends.
Bullish
- Strong Revenue Growth Trajectory: HCA's Q4 2025 revenue of $19.513 billion grew 6.72% YoY, with consistent sequential acceleration from $18.321 billion in Q1 2025. This demonstrates robust demand for healthcare services driven by an aging population.
- Expanding Profit Margins: Net margin improved to 9.62% in Q4 2025 from 7.86% a year ago, while operating margin expanded to 16.29% from 15.56%. This reflects operational efficiencies and favorable payer mix.
- Attractive Valuation on Forward Basis: Forward PE of 12.29x is well below the industry average of ~22x, and the PEG ratio of 0.57 suggests undervaluation relative to earnings growth. The stock trades at a 26% discount to sector median.
- Robust Free Cash Flow Generation: TTM free cash flow of $7.692 billion provides a FCF yield of ~7.1%, offering ample coverage for debt service and shareholder returns. This cash generation supports the company's leverage and buyback programs.
Bearish
- High Debt and Negative Equity: Debt-to-equity ratio of -8.33 reflects negative shareholders' equity due to aggressive buybacks and leverage. The current ratio of 0.83 indicates potential liquidity risk, though FCF mitigates this.
- Significant Underperformance vs Market: HCA's 1-year return of +7.47% lags the S&P 500's +20.63%, resulting in negative relative strength of -13.16%. The 3-month decline of -17.94% versus the S&P's +11.11% shows persistent weakness.
- Payer Mix and Regulatory Headwinds: Managed Medicare and Medicare together account for $6.325 billion of revenue, exposing HCA to government reimbursement cuts. Tenet Healthcare's recent soft Q1 sales due to unfavorable insurance mix highlight industry risks.
- Near 52-Week Low Price Action: At $406.59, the stock is only 23% above its 52-week low of $330.00 and 27% below the high of $556.52. The technical trend is bearish, with the stock in a corrective phase.
HCA Technical Analysis
HCA's 1-year price change of +7.47% masks a significant decline from its 52-week high of $556.52, with the current price of $406.59 representing 73.1% of the 52-week range. This positioning near the lower end of the range suggests the stock is in a corrective phase, potentially offering a value entry if fundamentals remain intact, but also reflecting bearish sentiment and selling pressure. The stock has underperformed the S&P 500, which gained 20.63% over the same period, resulting in a negative relative strength of -13.16% on a 1-year basis. Over the past 3 months, HCA has fallen 17.94%, while the S&P 500 rose 11.11%, indicating a sharp divergence and persistent weakness. The 1-month change of +8.91% offers a glimmer of recovery, but this is a short-term bounce from deeply oversold levels, not a confirmed trend reversal. The 3-month decline of -17.94% versus the 1-year gain of +7.47% suggests that the stock's long-term uptrend has been broken, and the recent momentum is bearish. The RSI is not provided, but the rapid decline from highs to lows implies oversold conditions that may attract dip-buyers. The 52-week low of $330.00 provides a critical support level, while the 52-week high of $556.52 is a distant resistance. A break above $556.52 would signal a resumption of the long-term uptrend, while a fall below $330.00 could trigger further downside. Beta of 1.128 indicates the stock is 12.8% more volatile than the market, meaning it amplifies market moves, which is important for risk management.
Beta
1.13
1.13x market volatility
Max Drawdown
-33.7%
Largest decline past year
52-Week Range
$330-$557
Price range past year
Annual Return
+1.9%
Cumulative gain past year
| Period | HCA Return | S&P 500 |
|---|---|---|
| 1m | -2.9% | +0.0% |
| 3m | -21.6% | +7.6% |
| 6m | -19.3% | +9.1% |
| 1y | +1.9% | +21.3% |
| ytd | -19.5% | +10.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HCA Fundamental Analysis
HCA's revenue trajectory remains solid, with Q4 2025 revenue of $19.513 billion, up 6.72% year-over-year from $18.285 billion in Q4 2024. The multi-quarter trend shows consistent growth: Q1 2025 revenue of $18.321 billion, Q2 2025 of $18.605 billion, Q3 2025 of $19.161 billion, and Q4 2025 of $19.513 billion, indicating acceleration from the mid-2024 levels. Revenue segments reveal that managed care and other insurers contribute the largest share at $9.536 billion, followed by managed Medicare at $3.478 billion and Medicare at $2.847 billion, highlighting the importance of commercial and government payer mix. The 6.72% YoY growth is healthy but decelerated from the 7.5% growth seen in Q2 2025, suggesting a slight moderation. HCA is highly profitable, with Q4 2025 net income of $1.878 billion and a net margin of 9.62%, up from 7.86% in Q4 2024. Gross margin improved to 41.9% from 41.4% a year ago, driven by operational efficiencies and favorable payer mix. Operating margin expanded to 16.29% from 15.56% in Q4 2024, reflecting cost control and scale benefits. The company's profitability is strong and improving, with net income growing 30.6% YoY from $1.438 billion. HCA's balance sheet shows a debt-to-equity ratio of -8.33, which is negative due to negative shareholders' equity (a common feature for highly leveraged companies with large share buybacks). The current ratio of 0.83 indicates potential liquidity risk, but the company generates robust free cash flow of $7.692 billion TTM, providing ample coverage for debt service and capital expenditures. Free cash flow per share is $3.77, and the FCF yield is approximately 7.1% based on current price, signaling strong cash generation. ROE is negative (-112.6%) due to negative equity, but ROA of 12.34% is healthy, indicating efficient asset utilization.
Quarterly Revenue
$19.5B
2025-12
Revenue YoY Growth
+6.7%
YoY Comparison
Gross Margin
41.9%
Latest Quarter
Free Cash Flow
$7.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HCA Overvalued?
Since HCA has positive net income, the PE ratio is the primary valuation metric. The trailing PE is 16.31x, while the forward PE is 12.29x, implying that the market expects earnings growth of approximately 32.7% over the next year. This gap suggests optimistic growth expectations are priced in. The PEG ratio of 0.57 indicates that the stock is undervalued relative to its earnings growth rate, supporting a bullish valuation case. Compared to the industry average (Medical - Care Facilities), HCA's trailing PE of 16.31x is below the sector median of approximately 22x, representing a 26% discount. This discount may be justified by HCA's higher leverage and regulatory risks, but its superior scale and margins argue for a narrower discount. Historically, HCA's trailing PE has ranged from 8x to 20x over the past five years. The current 16.31x is near the higher end of its historical range, suggesting the stock is not cheap on a historical basis, but the forward PE of 12.29x is more attractive. The PS ratio of 1.42x is below the 5-year average of 4.5x, indicating potential value, but this metric is less relevant for profitable companies.
PE
16.3x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~21x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: HCA's balance sheet is highly leveraged, with a debt-to-equity ratio of -8.33 due to negative shareholders' equity from extensive share buybacks. The current ratio of 0.83 indicates potential short-term liquidity pressure, though TTM free cash flow of $7.692 billion provides a strong cushion. Net income grew 30.6% YoY to $1.878 billion, but any slowdown in revenue growth (currently 6.72%) could strain debt service. The negative ROE of -112.6% is a structural concern, though ROA of 12.34% shows efficient asset use. Market & Competitive Risks: HCA trades at a forward PE of 12.29x, a 26% discount to the industry median of ~22x, but this discount could widen if sector sentiment deteriorates. Beta of 1.128 indicates 12.8% higher volatility than the market, amplifying downside in selloffs. Recent news of Tenet Healthcare missing revenue due to unfavorable payer mix highlights industry headwinds that could affect HCA's managed care and Medicare segments ($6.3B combined revenue). Regulatory risks include potential cuts to Medicare/Medicaid reimbursement rates. Worst-Case Scenario: A combination of payer mix deterioration, rising bad debt, and a recession reducing elective procedures could drive HCA's stock to its 52-week low of $330.00, representing a -18.8% decline from the current price of $406.59. In a severe downturn, historical max drawdown of -33.72% suggests a potential drop to $269.50, implying a -33.7% loss.
FAQ
The key risks for HCA Healthcare are: (1) Financial risk from high leverage – debt-to-equity of -8.33 and current ratio of 0.83 indicate potential liquidity stress, though FCF of $7.7B provides a buffer. (2) Regulatory risk – government payers (Medicare and managed Medicare) contribute $6.3B in revenue, making HCA vulnerable to reimbursement cuts. Recent industry commentary from Tenet Healthcare highlighted unfavorable payer mix as a headwind. (3) Market risk – beta of 1.128 means the stock amplifies market moves, and the 3-month decline of -17.94% shows significant downside momentum. (4) Competitive risk – as the largest hospital operator, HCA faces pricing pressure from insurers and competition from outpatient facilities. The most severe risk is a combination of regulatory cuts and a recession, which could drive the stock to its 52-week low of $330 (-18.8% from current).
The 12-month forecast for HCA Healthcare is moderately bullish, with a base case target range of $420-$480 (3.3%-18.1% upside) and 50% probability. This assumes revenue growth of ~5.5% to $97.96B and stable margins, with the stock trading at a forward PE of 12-14x. The bull case (25% probability) targets $480-$556 (18.1%-36.8% upside) driven by margin expansion and multiple expansion toward the industry average. The bear case (25% probability) targets $330-$400 (down 1.6%-18.8%) if earnings disappoint or regulatory headwinds materialize. The most likely scenario is the base case, supported by analyst consensus EPS of $48.73 and strong free cash flow. Key assumptions include sustained revenue growth above 5% and no major adverse regulatory changes. The AI assessment is bullish with medium confidence, citing the 26% valuation discount and PEG of 0.57.
HCA stock appears undervalued on a forward basis but fairly valued historically. The forward PE of 12.29x is well below the industry average of 22x, representing a 26% discount, and the PEG ratio of 0.57 suggests the market is not fully pricing in the company's earnings growth. However, the trailing PE of 16.31x is near the higher end of its 5-year historical range of 8x to 20x, indicating it is not cheap by its own history. The PS ratio of 1.42x is below the 5-year average of 4.5x, but this metric is less relevant for profitable companies. The market appears to be discounting HCA due to its high leverage (debt-to-equity -8.33) and regulatory risks. Given the strong free cash flow yield of 7.1% and growth trajectory, the stock is undervalued relative to peers and its growth rate, but the discount may persist until balance sheet concerns are addressed.
HCA Healthcare appears to be a good buy for value-oriented investors with a medium-term horizon. The stock trades at a forward PE of 12.29x, a 26% discount to the medical care facilities industry average of ~22x, and has a PEG ratio of 0.57, indicating undervaluation relative to its earnings growth. The company generates strong free cash flow of $7.7 billion (7.1% yield) and has delivered consistent revenue growth of 6.72% YoY with expanding margins. However, the stock has underperformed the market significantly (3-month -17.94% vs S&P +11.11%) and carries high leverage (debt-to-equity -8.33). The biggest downside risk is a further decline to the 52-week low of $330, representing an 18.8% loss. For investors willing to accept near-term volatility in exchange for a discounted valuation and solid fundamentals, HCA is a compelling buy. Conservative investors may prefer to wait for a clearer technical bottom.
HCA is better suited for medium-to-long-term investment rather than short-term trading. The stock's beta of 1.128 indicates higher volatility than the market, and the recent 3-month decline of -17.94% shows significant short-term risk. However, the company's fundamental strength – 6.72% revenue growth, expanding margins, and $7.7B free cash flow – supports a long-term hold. The dividend yield is low at 0.63%, so income seekers may look elsewhere. For long-term investors, a minimum holding period of 3-5 years is recommended to allow the operational momentum to overcome the leverage and regulatory concerns. Short-term traders could capitalize on the stock's volatility, but the current technical trend is bearish, with the stock near the lower end of its 52-week range. The PEG ratio of 0.57 and forward PE discount suggest that patient investors will be rewarded as the market recognizes the value.